AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Genetics Investing
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for Advanced Parkinson’s Disease Genetics Investing
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Genetics Investing